Pharma ETF or Biotech ETF: Which Matches Your Investing Mindset?
IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.
Overview
The iShares U.S. Pharmaceuticals ETF (NYSEMKT:IHE) offers a lower-cost entry into diversified pharmaceutical leaders, while the Invesco Biotechnology & Genome ETF (NYSEMKT:PBE) targets high-growth biotech and genetic engineering firms.
Both funds target the healthcare sector but with distinct strategic focuses. The healthcare sector often presents a choice between the high-growth potential of biotech and the established revenue streams of major pharmaceuticals. While both funds provide targeted exposure, they differ in portfolio construction and historical volatility profiles. Investors must decide between specialized innovation and larger pharmaceutical giants.
Details
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
Source
Originally published at www.fool.com.